MICHAEL STAMPER: Open Payments
NPI 1831318187 · THOMSON, GA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$753 in 51 payments from 13 companies in 2025. Trend: 2023 $394 · 2024 $507 · 2025 $753
Food & beverage: $753
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 18 | $186 |
| Novo Nordisk Inc | 12 | $147 |
| Bayer Healthcare Pharmaceuticals Inc. | 4 | $92 |
| Lilly USA, LLC | 4 | $71 |
| Verona Pharma, Inc. | 2 | $47 |
| PFIZER INC. | 2 | $40 |
| UCB, Inc. | 1 | $33 |
| Kowa Pharmaceuticals America, Inc. | 2 | $32 |
| Collegium Pharmaceutical, Inc. | 2 | $30 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $23 |
Products named: VRAYLAR, Ozempic, Kerendia, MOUNJARO, Ohtuvayre, PREVNAR 20, Briviact, ZORYVE.
Industry payments across GA — which companies pay providers there.
